Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $10.25.

Several brokerages recently issued reports on CMPX. Wedbush set a $4.00 price objective on Compass Therapeutics in a report on Wednesday, September 23rd. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. LADENBURG THALM/SH SH began coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 target price on the stock. Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Compass Therapeutics in the second quarter worth approximately $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics in the second quarter valued at approximately $12,771,670. BVF Inc. IL lifted its stake in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after acquiring an additional 3,014,842 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in Compass Therapeutics by 65.9% in the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock valued at $18,072,000 after acquiring an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP bought a new stake in Compass Therapeutics in the fourth quarter worth approximately $5,982,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Up 1.0%

CMPX stock opened at $0.99 on Friday. Compass Therapeutics has a 12-month low of $0.83 and a 12-month high of $6.88. The company has a market cap of $178.83 million, a price-to-earnings ratio of -2.48 and a beta of 1.02. The company has a 50 day moving average of $1.88 and a two-hundred day moving average of $2.58.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB.